Tibet AIM Pharm Yönetim

Yönetim kriter kontrolleri 2/4

Tibet AIM Pharm CEO'su Ke Xu, Sep2021 tarihinde atandı, in görev süresi 3.17 yıldır. şirketin hisselerinin 0.66% doğrudan sahiptir ve bu hisselerin değeri CN¥ 11.19M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 3.2 yıldır.

Anahtar bilgiler

Ke Xu

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.2yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

Some Confidence Is Lacking In Tibet AIM Pharm. Inc.'s (SZSE:002826) P/E

Jun 07

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

May 02

Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Feb 29

CEO

Ke Xu (46 yo)

3.2yrs

Görev süresi

CN¥724,100

Tazminat

Mr. Ke Xu serves as Chairman of Tibet AIM Pharm. Inc. since February 10, 2023. He serves as General Manager and Director of Tibet AIM Pharm.Inc. since September 13, 2021 and served as its Financial Direct...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ke Xu	GM & Chairman	3.2yrs	CN¥724.10k	0.66% CN¥ 11.2m
Yu Zhang	Deputy GM & Non-Independent Director	3.2yrs	CN¥301.20k	0.20% CN¥ 3.5m
Qianjin Li	Deputy GM & Secretary of the Board of Directors	3.2yrs	CN¥443.90k	0.10% CN¥ 1.7m
Zhou Min	Financial Director & Director	1.8yrs	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: 002826 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ke Xu	GM & Chairman	3.2yrs	CN¥724.10k	0.66% CN¥ 11.2m
Yu Zhang	Deputy GM & Non-Independent Director	3.2yrs	CN¥301.20k	0.20% CN¥ 3.5m
Zhou Min	Financial Director & Director	1.8yrs	Veri yok	Veri yok
Zhan Zhou	Vice Chairman	9.9yrs	CN¥301.20k	7.83% CN¥ 132.3m
Ming Hu	Independent Director	3.2yrs	CN¥200.00k	Veri yok
Xinggang Xiao	Independent Director	3.2yrs	CN¥200.00k	Veri yok
Lan Feng	Independent Director	3.2yrs	CN¥200.00k	Veri yok
Ling Li	Chairman of the Supervisory Board	3.2yrs	Veri yok	0.25% CN¥ 4.1m
Zhongbin Wang	Non-Employee Supervisor	3.2yrs	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002826 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Tibet AIM Pharm Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Tibet AIM Pharm. Inc., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Tibet AIM Pharm. Inc., Annual General Meeting, May 18, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.011 (vs CN¥0.066 in 3Q 2023)

Tibet AIM Pharm. Inc. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.061 (vs CN¥0.03 in 2Q 2023)

Tibet AIM Pharm. Inc. to Report First Half, 2024 Results on Aug 16, 2024

Some Confidence Is Lacking In Tibet AIM Pharm. Inc.'s (SZSE:002826) P/E

Tibet Aim Pharm. Inc. Announces Final Dividend on A Shares for the Year 2023, Payable on 31 May 2024

New minor risk - Profit margin trend

Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality

Tibet AIM Pharm. Inc., Annual General Meeting, May 17, 2024

Tibet Aim Pharm. Inc. Proposes Final Dividend for 2023

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.04 in 1Q 2023)

Investor sentiment deteriorates as stock falls 19%

Tibet AIM Pharm. Inc. to Report Q1, 2024 Results on Apr 26, 2024

Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Tibet AIM Pharm. Inc. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Tibet AIM Pharm. Inc. (SZSE:002826) announces an Equity Buyback for CNY 100 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.066 (vs CN¥0.087 in 3Q 2022)

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.03 (vs CN¥0.019 in 2Q 2022)

Tibet AIM Pharm. Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 07 July 2023

Tibet AIM Pharm. Inc. Approves Cash Dividend for 2022

Full year 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.22 in FY 2021)

High number of new and inexperienced directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.042 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.021 in 2Q 2021)

Tibet AIM Pharm. Inc. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 8 July 2022

Tibet AIM Pharm. Inc. Approves 2021 Profit Distribution Plan

Full year 2021 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in FY 2020)

High number of new and inexperienced directors

Tibet AIM Pharm. Inc., Annual General Meeting, May 18, 2022

Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for the Year 2021

Full year 2021 earnings released: EPS: CN¥0.24 (vs CN¥0.22 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.042 (vs CN¥0.02 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.041 in 2Q 2020)

Tibet AIM Pharm. Inc. (SZSE:002826) agreed to acquire 51% stake in Inner Mongolia Bositai Enterprise Management Service Co., Ltd. for CNY 30.6 million.

Tibet AIM Pharm. Inc. Approves Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.03 in 1Q 2020)

Tibet AIM Pharm. Inc. Proposes Final Cash Dividend for 2020

New 90-day low: CN¥8.25

New 90-day low: CN¥9.55

New 90-day low: CN¥10.42

New 90-day low: CN¥10.82

Third quarter earnings released

New 90-day low: CN¥11.11

Earnings released

Tibet AIM Pharm. Inc. to Report First Half, 2020 Results on Aug 26, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş